espite over six decades of speculation that inhibiting the degradation of insulin could offer new medicines for type 2 diabetes [1] [2] [3] , this concept has not yet been developed into a therapeutic strategy 4, 5 . Insulin-degrading enzyme (IDE, Fig. 1a ) is a widely expressed zinc-dependent metalloprotease that contributes to the proteolytic inactivation of insulin [4] [5] [6] . The precise delineation of the physiological roles of IDE on glucose regulation has been hampered by counterintuitive phenotypes observed in IDE -/-knockout studies, which may result from confounding effects on gene expression [7] [8] [9] or from other intracellular roles of IDE 4, 10 . The first examples of pharmacological inhibition of extracellular IDE using small-molecule inhibitors 11, 12 suggest that IDE-targeted therapeutics have potential to improve the regulation of blood glucose levels to treat type 2 diabetes by amplifying the surge of endogenous insulin following nutrient intake, even though basal blood glucose levels are not primarily modulated by IDE [4] [5] [6] . Since insulin is naturally released in amounts proportional to nutrient consumption during and after meals [4] [5] [6] , such a strategy offers a low risk of hypoglycemia 13 and may operate synergistically with current antidiabetic agents 11 . For example, combining drugs that boost glucose-stimulated insulin secretion, or insulin-sensitizing drugs, with extracellular IDE inhibitors might further decrease the need for regular insulin injections associated with treatment of type 2 diabetes.
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Previously, we reported the discovery and optimization of the first physiologically active IDE inhibitor, 6bK (1, Fig. 1b) , from a DNA-templated library of macrocycles 11 . Mutagenesis and X-ray crystallography studies revealed that 1 binds IDE at a previously unappreciated 'exo-site' binding pocket that is adjacent to but non-overlapping with the catalytic site 11 . Since this exo-site is not conserved among proteases, exo-site engagement confers the remarkable specificity of 1 for inhibiting IDE over other related metalloproteases 11 . We used this inhibitor to illuminate the physiological consequences of acute IDE inhibition in animal models of diabetes 11 . Treatment of mice with a single injection of 1 improved blood glucose clearance following oral glucose challenge, augmenting the effects of endogenous insulin release under experimental conditions that mimic a meal 11 . However, these and other studies revealed that IDE also degrades glucagon and amylin in vivo, in addition to insulin 2, 11, 14 and Aβ in the brain 8, 15 . Collectively, these observations suggest that developing a strategy for modulating IDE's activities on a subset of its endogenous substrates is critical to exploring the potential therapeutic benefits of IDE inhibition for the treatment of type 2 diabetes [8] [9] [10] [11] [12] [13] [14] [15] . Since glucagon elevates blood glucose levels and thus opposes the action of insulin, an ideal class of IDE-targeting diabetes therapeutics should preferentially block insulin degradation without impeding glucagon degradation 4, 11, 16 . Despite the discovery of many protease inhibitors as probes and therapeutic agents 17 , such substrate-selective inhibition of a protease has rarely been observed [18] [19] [20] [21] [22] . Therefore, the opposing physiological effects of IDE inhibition on two key glucose-regulating hormones that exist in the same extracellular environment present a paradox for the development of traditional small-molecule therapeutics that target IDE (Fig. 1a ) 4, 5, 11 . Two distinct classes of IDE inhibitors have emerged over the past decade 5 . Traditional metalloprotease inhibitor designs use a hydroxamic acid or other zinc-chelating group to interfere directly with the biochemical mechanism of this zinc-dependent protease (for example, Ii1 (2), Fig. 1b ) 23, 24 . Despite the observation of activesite inhibitors that block IDE more strongly in the presence of Aβ, a way to substrate-selectively inhibit IDE-mediated insulin cleavage has not been reported [25] [26] [27] . Recently discovered exo-site inhibitors, including 1 and others 12, 28, 29 , do not interact with the catalytic zinc ion or otherwise block the catalytic site, but instead function as competitive inhibitors by occupying part of the substrate-bind-Articles NaTUrE CHEmICal BIology ing cavity 11 . In principle, exo-site inhibitors raise the possibility of maintaining IDE's proteolytic activity while reshaping its substrate selectivity (Fig. 1a) , but this possibility has not been realized. We hypothesized that the identification of small-molecule exo-site ligands could provide a starting point to develop substrate-selective IDE inhibitors that preferentially block insulin degradation, without substantially impeding glucagon degradation. To date, substrateselective inhibition has not been systematically implemented in therapeutics discovery and development, despite the potential of this approach to modulate biology downstream of the many known poly-substrate-specific targets in a sophisticated manner that cannot be achieved by blocking protein active sites. Before this work, only a handful of unoptimized ligands for disparate protein targets have been reported to be substrate-selective inhibitors (SSIs) (listed in Supplementary Table 1) 18 -22,30-32 . Moreover, the structural basis underlying substrate-selective mode of inhibition and methods to generate such inhibitors remain largely unexplored.
Results
An exo-site-specific screen reveals new IDE inhibitors. Toward this goal, we designed a high-throughput screen to identify smallmolecule IDE exo-site ligands by displacement of a fluorescent probe that binds away from IDE's catalytic residues (Fig. 1b and  Supplementary Table 2) 33 . To construct this probe, we replaced the linker attached to DNA in the original DNA-templated macrocycle library hit 6b (3) with a fluorescein group 11 . The resulting probe, FL-6b (4) retained strong binding activity to IDE (half-maximum inhibitory concentration in a fluorogenic decapeptide cleavage assay (IC 50 fluo ) = 100 nM) 11 . The interaction of probe 4 (5 nM) with human IDE (0.5 µM) resulted in elevated fluorescence anisotropy. This anisotropy signal decreased upon displacement of 4 with an excess of the non-fluorescent exo-site inhibitor 1 (1 µM). When conducted in 384-well microtiter plates, this assay resulted in a robust signal suitable for high-throughput screening (Z-factor = 0.7, Supplementary Fig. 1 ) 31, 33 . The potent zinc-chelating IDE inhibitor 2 (Fig. 1b) 
23
, which, unlike 1, binds the catalytic site rather than the exo-site, does not displace 4 and did not cause any change in fluorescence anisotropy. These results establish an exo-site-specific high-throughput screen for discovery of new IDE exo-site-binding ligands.
Using this assay, we conducted a pilot screen using a collection of 9,598 small molecules that represents the structurally diverse chemical libraries within the Broad Institute ( Supplementary  Fig. 1 ) 34 . The pilot screen revealed a number of weakly active hits (Supplementary Data Set 1 and PubChem BioAssay 1259349), primarily from azetidine-based libraries 34 , which feature biaryl appendages resembling the critical benzophenone group of the DNA-templated macrocyclic IDE inhibitor 1 (Fig. 1b) 
11
. On the basis of these results, we conducted an expanded screen on the full collection of 8,959 azetidine-core compounds 34 ( Fig. 1c) , resulting in 12 hits with average Z-scores similar to those of the positive control 1 (Fig. 1c) among 100 structurally related compounds that also produced a significant decrease in the anisotropy signal. As an initial secondary screen, these compounds were individually tested for IDE inhibition using an proteolysis reporter-based assay (substrate Mca-RPPGFSAFK(Dnp)-OH) 35 . The top hits were all active IDE inhibitors, ranging in inhibitory potency at half-maximum effective concentration in fluorogenic decapeptide cleavage assay (EC 50 fluo ) = 0.1 to 5 µM 36 (Supplementary Data Set 1 and PubChem  BioAssay 1259348; see Supplementary Table 2 and Supplementary  Fig. 1 for a summary of the secondary screening strategy).
IDE cleavage assays using the decapeptide reporter in the presence of exo-site ligands revealed partial IDE inhibition activity even at saturating inhibitor concentrations, with maximal inhibition (I MAX ) 36 below 100% (Supplementary Data Set 1 and PubChem BioAssay 1259348). The most potent screening hits, BRD8283 (5, EC 50 fluo = 0.1 µM, I MAX = 67%), 6 (EC 50 fluo = 0.4 µM, I MAX = 73%) and BRD2878 (7, (EC 50 fluo = 0.34 µM, I MAX = 40%) share the same macrocycle-fused azetidine core (Fig. 1c, insets ) 34 and represent a structurally related collection of small-molecule exo-site ligands that could potentially alter the substrate selectivity of IDE.
IDE exo-site ligands that alter substrate selectivity. Next, we prioritized identifying compound scaffolds that support the complete blockage of IDE-mediated cleavage of human insulin, but not glucagon, and considered maximizing IDE inhibition potency as a secondary goal for subsequent optimization. We tested a structurally representative group of IDE exo-site ligands, including those mentioned above, for their ability to impede IDE-catalyzed degradation of unmodified full-length hormone substrates using homogeneous time-resolved Förster resonance (HTRF) energy transfer through paired fluorophore-conjugated monoclonal antibodies 37 ( Fig. 1d and Supplementary Fig. 2 ). As expected, in these assays the competitive inhibitor 1 effectively blocked the degradation of either insulin or glucagon with similar potency (Fig. 1e) , while IDE alone depleted both substrates to a similar extent. Two exo-site-binding azetidines, 5 and BRD4171 (6), fully prevented IDE-mediated insulin degradation preferentially over glucagon degradation (Fig. 1d) . Unlike other exo-site ligands we identified, or any IDE ligand previously reported, 5 and 6 fully blocked insulin degradation in a concentration-dependent manner, while only weakly and partially inhibiting glucagon degradation ( Fig. 1f and Supplementary Fig. 2 ). In addition to favorable discrimination of insulin versus glucagon, these compounds also exhibited modest levels of substrate-selective inhibition in assays with two other IDE substrates, amylin and Aβ40 ( Supplementary Fig. 2 ) 8, 15 . Together, these results establish the discovery of two second-generation IDE inhibitors that selectively inhibit IDE-mediated degradation of insulin over glucagon. comprising four homologous domains that create a large internal cavity (blue mesh). The therapeutic outcome of IDE inhibition arises from impeding the degradation of insulin (red double arrow), rather other in vivo IDE substrates (drawn to scale). The red sphere is the bound zinc ion in the catalytic site. b, Macrocyclic peptide 6bK (1), zinc-chelating peptidic inhibitor Ii1 (2) 23 and fluorescent high-throughput screening probe FL-6b (4) based on DNAtemplated macrocycle hit 6b (3) 11 . c, Small-molecule screen for displacement of 4 from human IDE. The x and y axes show anisotropy Z-scores from two replicates for 7,679 azetidines; see Supplementary Figs. 1 and 2 for screening results on all 17,277 compounds tested. Primary assay data and counterscreening results are deposited in PubChem BioAssay databases 1259349 and 1259348, respectively (Supplementary Data Set 1). d, IDE-mediated insulin versus glucagon depletion (green and red heatmaps, respectively), measured using HTRF energy transfer with paired labeled antibodies for each substrate in the presence of hit compounds (tested at 67 µM, >ten-fold EC 50 fluo ). e,f, Concentration-dependent profiles for known macrocyclic inhibitor 1 and BRD8283 (5) in IDE-mediated degradation assays for insulin and glucagon. See also Supplementary Fig. 2 for additional substrate degradation assays using 1, 5, BRD4171 (6) and BRD2878 (7), respectively. g, Fluorogenic peptide cleavage assays reveal >1,000-fold specificity of 5 for IDE (EC 50 fluo = 100 nM, I MAX = 65%) over all other metalloproteases tested: THOP, NLN, NEP, MMP1 and ACE. See also Supplementary Fig. 2 for the protease specificity profile of 6(>500-fold specificity). All assays include IDE alone in 2% v/v DMSO as the no-inhibitor activity reference. Points and error bars represent mean ± s.e.m. for three technical replicates (e,f), or two technical replicates in the additional metalloprotease assays (g) and substrate depletion heatmaps (d). EC 50 values are reported for endpoint degradation assays and for partial inhibitors, whereas IC 50 values are calculated for kinetic assays with normal inhibitors 36 .
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To confirm that this class of inhibitors interacts with the exo-site, rather than the catalytic site, we assayed their ability to inhibit IDE mutants such as A479L, in which the leucine side chain is predicted to fill the distal hydrophobic pocket of the exo-site without interfering with IDE's proteolytic activity 11 . These assays revealed that 5 and 6 inhibit wild-type IDE, but do not inhibit A479L exo-site variants ( Supplementary Fig. 2 ). These two inhibitors also displayed decreased affinity for IDE containing G362Q or I374Q mutations, consistent with a model in which these compounds occupy the exosite region demarcated by these residues, that is, >16 Å away from the zinc-dependent catalytic site ( Supplementary Fig. 2) 
11
. Assays against related and unrelated zinc-metalloproteases, including neurolysin (NLN), thimet oligopeptidase (THOP)1, neprilysin (NEP), matrix metalloprotease 1 (MMP1) and angiotensin-converting enzyme (ACE) revealed that 5 and 6 ( Fig. 1g and Supplementary  Fig. 2 ) inhibit IDE with a high degree of selectivity (≥500-fold) BRD8283 (5) BRD4171 (6) BRD2878 (7) BRD7049 (8) BRD8725 (9) BRD9790 (10) BRD8780 (11) BRD0568 (12) BRD9088 (13) BRD3969 (14) BRD4187 (15) BRD8410 (16) BRD0500 (17) BRD8620 (18) BRD7862 (19) BRD6262 ( Articles NaTUrE CHEmICal BIology over other metalloproteases, further consistent with their ability to engage the exo-site, which is not conserved among proteases, rather than the catalytic site of IDE. These results collectively establish a family of small-molecule bicyclic azetidines as exo-site inhibitors that can alter the substrate selectivity of IDE, and specifically block IDE-mediated degradation of insulin.
Optimization of substrate-selective IDE inhibitors. On the basis of the primary screen data, we chose 5 (EC 50 fluo = 0.1 µM, I MAX = 67%) as a starting point to probe and optimize the determinants of potency and substrate selectivity (Fig. 2a-c) . We began by altering the substitution pattern of the biaryl rings (analogs 20-36). Early rounds of optimization revealed that analogs with ortho-methylsubstituted biaryl appendages displayed a >65-fold improvement in affinity, exemplified by compound 30 (EC 50 fluo = 1.5 nM, I MAX = 60% inhibition of fluorogenic decapeptide proteolysis, Fig. 2a) . We speculate that this substitution pattern favors a non-planar relationship between the rings of the biphenyl group. Since our previous crystal structure suggested that the aryl rings of the benzophenone group of 3 must bind the exo-site in a perpendicular conformation 11 , we hypothesize that ortho-methyl substitution of the terminal phenyl group causes these compounds to adopt a similar conformation before binding IDE, thereby reducing the entropic cost 38 of adopting this conformation when bound to IDE.
We next probed other structural features of these compounds, including the azetidine-fused macrocycle linker, the effect of R 2 group hydrogen bond donor and charge, and the sulfonamide appendage R 4 ( Fig. 2b,c) . The structure-activity relationships among analogs 37 to 63 collectively suggest a model in which the rigid bicyclic-azetidine core contributes to optimal affinity and inhibitor potency beyond acting as a scaffold for appendages, with a basic azetidine nitrogen that is a favorable but non-essential feature and an R 2 group that may be solvent-exposed but that is capable of interacting with the exo-site through a hydrogen bond. Moreover, aryl-sulfonamide appendages (R 4 ) bearing ortho-methyl groups, such as N-methyl-imidazole-2-sulfonamide, are present in several potent inhibitors. The most potent substrate-selective IDE inhibitor 63 (EC 50 fluo = 0.5 nM, I MAX = 60%) 36 integrated all four of the favorable structural features elucidated from the structure-function analysis (Fig. 2c) . The third-generation IDE exo-site inhibitors 30, 37 and 63 maintained the ability to inhibit insulin degradation over glucagon degradation, similar to that of 5 throughout the stepwise potency optimization process (Fig. 2d) .
With potent substrate-selective exo-site ligands in hand, we sought to study in greater detail the concentration-dependent IDEmediated insulin and glucagon degradation assays in the presence of analogs 37 and 63 (Fig. 3a , EC 50 fluo = 1 nM and 0.5 nM, respectively, and see Supplementary Fig. 2 for compound 30) . The most notable difference in glucagon versus insulin degradation assays, as observed with 5 and 6, in contrast to the non-substrate-selective IDE inhibitor 1 (Fig. 1e,f) , was the persistent IDE proteolytic activity on glucagon spanning several orders of magnitude of concentrations of compounds 30, 37 and 63 (Fig. 3a-c and Supplementary  Fig. 2 ). Indeed, IDE-mediated processing of glucagon reached 60%, 29% and 50% depletion over the 10-minute assays, respectively, at saturating inhibitor concentrations (Fig. 3b,c and Supplementary  Fig. 2 , also compare with 5 in Fig. 1f) . Moreover, the EC 50 inflection points of the glucagon cleavage assays for 30, 37 and 63 were 10-30-fold higher than in the respective insulin degradation assays, which showed complete competitive inhibition of insulin degradation by 30, 37 and 63, with calculated K i comp = 6 nM, 4.3 nM and 1.7 nM, respectively ( Table 4 ). These data demonstrate that the biochemical effects of SSIs can extend beyond a substrate-dependent shift of the EC 50 inflection point to preserve the processing of certain substrates even at saturating inhibitor concentrations, unlike the nearly identical glucagon and insulin degradation curves observed for the non-substrate-selective IDE inhibitor 1 (Fig. 1e) . Additionally, SSIs prevent IDE-mediated insulin degradation for more than 1 hour, No. . These findings indicate that ternary complexes comprising human IDE, glucagon and a substrate-selective exo-site inhibitor are catalytically competent.
To our knowledge, these compounds represent SSIs with the highest potency and specificity for their target reported to date for any enzyme (Supplementary Table 1 ), demonstrating that substrateselective inhibition is not exclusively a property relegated to weak ligands that can be differentially outcompeted from target binding by higher affinity substrates [18] [19] [20] [21] [22] [30] [31] [32] . The optimized analogs 30, 37 and 63 inhibit IDE with exquisite specificity (≥10,000-fold) over all other related and unrelated metalloproteases tested, including NLN, THOP1, NEP, MMP1, ACE and nardilysin (NRDC) (Fig. 2d,e and Supplementary Fig. 2 ). This observation is consistent with their high affinity for the IDE exo-site, which is a distinctive feature not conserved among other proteases, unlike the similarity among catalytic sites of metalloproteases 40 . We also subjected SSI 63 at 1 and 10 µM concentrations to assays on an unbiased panel of 18 human metalloproteases and observed minimal inhibition, in contrast to that of catalytic site zinc-chelating IDE inhibitor 2 (refs. 11, 23 ) (Supplementary Table 6 and Supplementary Data Set 2). These data further support the target selectivity advantages of inhibiting an exo-site rather than the active site. Taken together, our data establish that targeting IDE's exo-site can give rise to small-molecule ligands with a superior combination of high potency, high metalloprotease specificity and substrate-selective inhibition compared to previously described IDE inhibitors 5, 11, 12, 23, 24, [26] [27] [28] [29] .
Molecular basis of substrate-selective inhibition. Finally, we sought to illuminate the molecular basis of substrate-selective IDE inhibition. We solved the X-ray co-crystal structure of the wellestablished catalytically inactive E111Q, cysteine-free form of IDE 35 bound to SSIs 37 and 63 (at 2.96 and 3.49 Å resolutions, respectively), as well as the co-crystal structure of the IDE-63-glucagon ternary complex at 3.18 Å resolution (Fig. 4a, Supplementary Video Table 7 ). These structures revealed that SSIs 37 and 63 bind to the same exo-site pocket as 3, more than 16 Å away from the nearest catalytic residue (Fig. 4a,b and Supplementary Fig. 3 ). The interactions observed between IDE and the inhibitors are consistent with the observed structure-activity relationships (Fig. 2a-c) , including the conformationally locked biaryl rings of SSIs 37 and 63 filling a hydrophobic tunnel near the exo-site and the sulfonamide appendages binding a hydrophobic patch adjacent to the exo-site beta-sheet β12 (Fig. 4a,c) . Fig. 2 for expanded substrate-selectivity profiles including amylin and Aβ . d,e, Metalloprotease specificity of 37 and 63, determined using fluorogenic peptide cleavage assays, display >10,000-fold specificity for IDE over all other metalloproteases tested: THOP1, NLN, NEP, MMP1, ACE and NRDC. Supplementary Table 6 includes additional metalloproteases assayed in the presence of 63 (1 and 10 µM) and 2 (1 µM). See also Supplementary Fig. 2 for insulin-glucagon degradation assays and the metalloprotease specificity profile for analog 30, which also displays >10,000-fold specificity. All assays include IDE alone in 2% v/v DMSO as the no-inhibitor activity reference. Values and error bars reflect mean ± s.e.m. of three technical replicates (b,c) or two technical replicates in the additional metalloprotease assays (c,d).
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The protein structure of IDE bound by 37, 63 or by 63-glucagon, adopted a closed conformation nearly identical to that of wild-type IDE and IDE alone, as well as the IDE-3 co-crystal structure and other previously reported IDE structures ( Supplementary Fig. 4 ) 40, 41 . The structure of the ternary complex of IDE-63-glucagon reveals the N terminal residues of glucagon binding to IDE's exo-site betasheet β12 via backbone-backbone hydrogen bonding interactions ( Fig. 4d and Supplementary Figs. 3 and 4) adjacent to SSI 63, precisely matching the pattern of interactions previously reported in the IDE-glucagon structure (Protein Data Bank (PDB) ID 2G49) 40 . Likewise, we observed the expected additional interactions for the C terminal residues of glucagon in the catalytic groove of IDE ( Fig. 4a and Supplementary Figs. 3 and 4 ) 40 . As previously reported in the IDE-glucagon structure 40 , the central section of glucagon that extends between the exo-site and the catalytic site is also disordered in the IDE-63-glucagon ternary complex (Fig. 4c, dotted line  represents unresolved residues) ; therefore, no other interactions are observed between the ligand 63 and glucagon 40 . In contrast, superimposition of the IDE-SSI structures with a partially folded insulin molecule from the reported IDE-insulin structure (Fig. 4d , PDB ID 2WBY) 40 or with unfolded insulin molecules from IDEinsulin cryo-electron microscopy structures (Fig. 3e,f , PDB IDs 6BFC, 6B3Q) 42 predict that the space occupied by the inhibitors' aryl-sulfonamide appendages (R 5 ) and macrocycle linker sections (R 3 /R 4 ) would clash with an IDE-bound insulin molecule. Similar views from overlays of amylin-IDE and Aβ-amyloid-IDE co-crystallized substrates (Fig. 4g,h , PDB IDs 2G48, 2G47) 40 suggest an intermediate extent of proteolysis is possible in the presence of 37 and 63 (Supplementary Fig. 2 ). These models are consistent with the above biochemistry data showing that 37 and 63 competitively block insulin binding to the IDE cavity in a mutually exclusive manner (Fig. 2b,c and Supplementary Fig. 3 ). These results together reveal the substrate-dependent interactions that underlie the structural basis of substrate-selective IDE inhibition. . c, View of the exo-site in the IDE-63-glucagon co-crystal structure showing the space-filling model of glucagon (red). The dashed red line represents disordered residues in the central section of glucagon (see Supplementary Figs. 3 and 4) . d-h, Matching views of the exo-site of IDE bound by 63 in which glucagon has been cloaked, and shown instead with superimposed substrates from published IDE-substrate cocrystal structures 40, 42 . d, The superimposition with partially folded insulin bound to IDE (green, PDB ID 2WBY). e, With unfolded insulin α-chain from cryo-EM insulin-IDE structure (green; PDB ID 6BFC). f, With unfolded insulin β-chain from cryo-EM insulin-IDE structure (green; PDB ID 6B3Q). g, With amylin bound to IDE (PDB ID 2G48; cyan surface). h, With Aβ(1-40) bound to IDE (PDB ID 2G47; purple surface) 40, 42 . Supplementary Fig. 3 includes complementary analyses for the X-ray co-crystal structures of IDE-37 and IDE-63 co-crystallized without glucagon. See the Supplementary Video associated with this figure.
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To investigate the possibility of conformational allostery as a contributor to substrate-selective inhibition, we superimposed the IDE-63 and IDE-63-glucagon co-crystal structures with the apo-IDE structure (Fig. 5 and IDE-37 in Supplementary Figs. 3 and 4) . The SSIs do not alter the conformation of IDE, and thus do not induce allosteric changes in the protein. Analysis of the superimposed zinc-dependent catalytic domain 1 of IDE using distance-difference matrix calculations reveals the absence of allosteric changes (Fig. 5a,c, see also Supplementary Figs. 3 and 5) , in contrast to the pronounced long-distance conformational changes in the catalytic site induced by a Fab bound to IDE domain 2 (Fig. 5b,d , PDB ID 4IOF, see Supplementary Fig. 5 ) 42 . These observations were corroborated by all three co-crystal structures solved in this study, demonstrating that exo-site-targeted macrocyclic inhibitors and substrate-selective IDE inhibitors act differently from allosteric inhibitors that modulate protein conformation and typically abrogate functions of the catalytic site by inducing distal conformational changes [42] [43] [44] [45] [46] . A detailed comparison of the superimposed poses of the IDE-glucagon and the IDE-63-glucagon structures show that only a minor bond rotation of the Gln-3 side chain of glucagon has occurred to accommodate for the formation of the IDE-63-glucagon ternary complex, while preserving the cross-beta-sheet interactions between the backbone of the substrate and exo-site beta-sheet β12 (Fig. 5e ) 40 as well as the previously reported interactions of glucagon in the catalytic site of IDE ( Supplementary Figs. 4) 
40
.
Taken together, these findings strongly support a model of substrate-selective inhibition in which glucagon avoids steric clashes with substrate-selective ligands within IDE, consistent with the efficient catalytic processing of glucagon by IDE under conditions of ligand saturation (Fig. 3a-c) . The same analysis for the macrocycle 6b-IDE co-crystal structure predicts major steric clashes between 3 and both insulin and glucagon ( Supplementary Fig. 3 ), explaining the inability of bulky inhibitors to substrate-selectively inhibit IDE (Fig. 1e) 
11
. Collectively, these results provide a structural basis for the substrate-selective inhibition of IDE by third-generation exosite ligands and identify key structural features of IDE inhibitors that result in this property.
To investigate whether the cleavage site of glucagon is altered by the presence of SSIs, we evaluated IDE reactions quenched at various timepoints to capture the first cleavage products of IDE alone or in the presence of SSI 37 (10 µM, >10,000-fold EC 50 fluo ), and control inhibitors 1 (10 µM) or 2 (1 µM) (Supplementary Fig. 6 ). Mass spectrometry analysis using MALDI-TOF revealed a nearly identical distribution of glucagon cleavage products in the presence or the absence of saturating concentrations of 37, primarily resulting from proteolysis between Arg17-Arg18, as well as minor cleavage at Arg18-Ala19 as previously reported (labeled in Fig. 5f , full data in Supplementary Fig. 6) 
47
. Similar to the observation using antibody assays (Fig. 3b) , the relative ion intensities qualitatively indicated that at ligand saturation the rate of the ternary complex of wild-type-IDE-37-mediated glucagon cleavage was approximately 50% the rate of IDE-mediated glucagon cleavage in the absence of inhibitor, whereas 1 and 2 each fully inhibited glucagon cleavage ( Supplementary  Fig. 6 ). These observations are consistent with previous studies that showed IDE-substrate binding and catalysis are sequential but independent steps in which the former is rate-limiting for glucagon proteolysis due to its modest binding affinity for IDE 35, 40 . The substrate-selective competition model (Fig. 4c versus 4d-f ) predicts that IDE bound by a substrate-selective exo-site ligand should predominantly cleave smaller peptide substrates even in the presence of excess insulin, which can no longer occupy IDE's substrate-binding cavity. To test this mechanistic prediction we used the fluorogenic decapeptide substrate as a reporter of IDE activity 35 , and tested the ability of SSIs to redirect IDE's activity to process this low-affinity substrate instead of insulin, the highest-affinity substrate of IDE 6, 39 . The IDE-63-glucagon ternary structure also predicts that excess glucagon under the same set of conditions should still bind IDE, outcompeting the fluorogenic reporter peptide and produce no signal. We incubated IDE with excess human insulin or human glucagon (50 µM final concentration) followed by the addition of the fluorogenic decapeptide reporter substrate (5 µM), which resulted in a low fluorescence signal due to its low affinity for IDE compared to the hormone substrates (Fig. 5g) 
35
. As predicted by the substrate-selective inhibition model, IDE-mediated cleavage activity was redirected in the presence of insulin, but not glucagon, toward the small fluorogenic peptide when treated with saturating concentrations of SSIs 30, 37 or 63 (Fig. 5g , cleavage rates of 40-60% compared to DMSO control and minimally affected by the introduction of excess insulin). These data exclude an alternative co-substrate uncompetitive mechanism that could arise from an inactive ligandenzyme-insulin complex that would prevent the catalytic cycle of IDE, as observed in other systems that do not operate through bona fide substrate-selective inhibition 25 . Taken together, these findings reveal that the unique ability of SSIs to reshape IDE's substrate recognition mechanisms stems from substrate-specific steric clashes and competitive exclusion of insulin from the substrate-binding exo-site region of IDE, while small and flexible substrates such as glucagon can still assemble with IDE and the SSI in a partial mixednoncompetitive mode of inhibition that allows unobstructed processing of glucagon by the catalytic center >16 Å away. 42 . c,d, Distance-difference matrix heatmaps calculated for domain 1 Cα-to-Cα motions between the superimposed structures in a and b, which are set to the same reference scale to reveal the lack of allosteric effects of 63-bound IDE domain 1 (c), compared to the domain-1 allosteric effects previously observed with the Fab targeting IDE domain 2 (d). Supplementary Fig. 5 includes complementary distance-difference matrix heatmaps for the full protein domains 1-4 that shows the comparison of the relative motions of the N and C terminal halves for Fab-bound IDE, but not in the presence of 37 or 63. e, Detailed view of the predicted rotation of the Gln3 side chain (curved arrow) that accommodates binding of glucagon in the IDE-63-glucagon ternary complex (red sticks), compared to the overlay of glucagon modeled from the glucagon-IDE structure (yellow sticks, PDB ID 2G49) 40 . Additionally, a co-crystallized polypeptide (modeled as Ala 3 ) is observed in the cavity of the IDE-37 structure interacting with the same beta-sheet β12 of IDE's exo-site ( Supplementary Fig. 3 ). The mesh represents the composite omit electron density map of ligand 63 contoured at 1σ. The exo-site residues that were mutated to interrogate binding of the inhibitors are highlighted with matching colors to the IDE variant inhibition data shown in Supplementary Fig. 2f ,g. f, Major (black scissors) and minor (gray scissors) cleavage sites of glucagon by IDE in the presence or absence of 37 (10 µM) as determined by MALDI-TOF mass spectrometry (see Supplementary Fig. 6 ). g, Proteolytic activity of wild-type human IDE reported by the rate of cleavage of the fluorogenic decapeptide substrate (Mca-RPPGFSAFK(Dnp)-OH) in the presence or absence of human insulin (green filled and dashed bars, respectively, 50 µM Humulin-R) or in the presence or absence of human glucagon (red filled and dashed bars, respectively, 50 µM GlucaGen) when combined with 10 µM each of SSIs 30, 37 and 63, with competitive inhibitor 1, or the zinc-chelating inhibitor 2 (ref. 23 ). A 2% v/v DMSO-alone mixture with IDE was the activity reference and negative control. Points represent three technical replicates. h,i, Inhibition model of exo-site SSIs in the presence of an allowed substrate (Glu, glucagon, left) or a blocked substrate (Ins, insulin, right) (h), compared to the inhibition model of a generic allosteric ligand driving a target enzyme (E act ) into a conformationally inactive state (E inact ) (i).
Articles
NaTUrE CHEmICal BIology
Discussion
This study integrates insights from biochemistry, small-molecule screening, medicinal chemistry and structural biology to develop and characterize a unique series of potent and specific drug-like molecules that substrate-selectively block IDE and redirect its proteolytic activity toward substrates other than insulin. These discoveries unlock the potential of IDE-targeting therapeutics for type 2 diabetes to avoid the paradoxical effects of blocking the degradation of glucagon as a glucose-elevating hormone 11 , as well as other substrates that may not yet be established be regulated by IDE 8, 14 . The SSIs reported here represent a pharmacological solution that mitigates IDE's polyspecificity toward opposing glucose-modulating substrates by supporting glucagon cleavage at all tested concentrations of inhibitor, including saturating levels. Exo-site engagement by SSIs enables substrate-dependent interactions that potently block insulin binding (Fig. 5h, right) while allowing the formation of a catalytically competent IDE-inhibitor-glucagon ternary complex (Fig. 5h, left) . This mode-of-inhibition contrasts with traditional allostery mechanisms (Fig. 5i) More broadly, this study may serve as a blueprint to identify substrate-selective exo-site inhibitors of other enzymes that bind their substrates through interactions not entirely tied to the catalytic site, including some kinases, phosphatases, peptidases, sheddases, metalloenzymes, ubiquitin ligases and conjugating enzymes, among others 20, 21, [30] [31] [32] 46, [48] [49] [50] . The development of SSIs thus could enable therapeutic modulation of enzymes that operate on multiple substrates and that contain at least one exo-site mediating enzymesubstrate interactions. This strategy could enable biological roles of enzymes to be tailored not by the traditional approach of abolishing catalytic activity, but instead by the more precise approach of reprogramming substrate specificity.
online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41589-019-0271-0. 11 was cloned into the expression plasmid pTrcHis-A (Invitrogen) using primers for uracil-specific excision reactions and Phusion U Hot-Start DNA-polymerase (ThermoFisher F555S) 51 . Mutant IDE constructs were generated by amplifying the complete pTrcHis-A-hIDE vector construct with uracil-specific excision reaction cloning primers introducing a mutant overhang (Supplementary Table 8 ) as previously described 11 and introduced by heat shock into NEB turbo Escherichia coli cells. Transformants were selected on carbenicillin Luria-Bertani agar, and isolated colonies were cultured overnight in 2 ml LB media. Plasmids were extracted using a microcentrifuge membrane column kit (Miniprep, Qiagen), and the sequence of genes were confirmed by Sanger sequencing 11 . The plasmid constructs were transformed by heat shock into chemically competent expression strain Rosetta 2 (DE3) pLysS E. coli cells (EMD Millipore) and selected on carbenicillin/chloramphenicol LuriaBertani agar. Cells transformed with IDE pTrcHis-A constructs were cultured overnight at 37 °C in 2xYT media (31 g in 1 l) containing 100 μg ml −1 ampicillin and 34 μg ml −1 chloramphenicol. Expression of His 6 -tagged IDE proteins was induced when the culture reached an OD 600 of ~0.6 by addition of IPTG to 1 mM final concentration. The cells were incubated overnight at 37 °C, then centrifuged at 10,000g for 30 min at 4 °C.
Recombinant His 6 -tagged proteins were purified by Ni(II)-affinity chromatography (IMAC sepharose beads, GE Healthcare) according to the manufacturer's instructions. The cell pellets were resuspended in pH 8.0 buffer containing 50 mM phosphate, 300 mM NaCl, 10 mM imidazole, 1% Triton X-100 and 1 mM tris(2-carboxyethyl)phosphine hydrochloride, and were lysed by probe sonication for 4 min at <4 °C, followed by clearing of cell debris by centrifugation at 10,000g for 25 min at 4 °C. The supernatant was incubated with Ni(II)-doped IMAC resin (2 ml) for 3 h at 4 °C. The resin was washed twice with the cell resuspension/lysis buffer and three times with pH 8.0 buffer containing 50 mM phosphate, 300 mM NaCl, 50 mM imidazole and 1 mM tris(2-carboxyethyl) phosphine hydrochloride. Elution was carried out in 2 ml aliquots by raising the imidazole concentration to 250 mM and subsequently to 500 mM in the previous buffer. The fractions were combined and the buffer was exchanged to the recommended IDE buffer (R&D) using spin columns with 100 KDa molecular weight cut off membranes (Millipore). Protein yields were typically ~10 µg l −1 and >90% purity on the basis of gel electrophoresis analysis (Coomassie stained). IDE-specific protease activity was >95% as assessed by inhibition of degradation of peptide substrate Mca-RPPGFSAFK(Dnp)-OH (R&D) by 20 µM of inhibitor 1, and compared with commercially available human IDE (R&D) under the same conditions.
Fluorescence anisotropy high-throughput screening assay. Human N-His 6 -IDE 42-1019 (E. coli expressed) was mixed with fluorescein-labeled macrocycle 4 in 50 mM Tris buffer pH 8.0, with 1 M NaCl at 25 °C. The optimum signal was obtained using 0.5 µM IDE (Supplementary Fig. 1 ) and 5-30 nM of probe 4 depending on the spectrophotometer used (excitation 492 nm, emission 523 nm). The pilot screen using the Broad Institute 'DOS Informer Set' compound collection was transferred by pinning (100 nl per well) into 384-well plates containing the enzyme-probe mixture (50 µl per well, 0.5 µM IDE, 30 nM 4) using a CyBio Vario liquid handling system equipped with a pin-transfer workstation and a Multidrop Combi-nL Reagent Dispenser (Thermo Scientific). For the second screen using azetidine-core libraries the compounds were preloaded in empty 384-well plates by sonication using an Echo 555 Liquid Handler (Labcyte) and the enzyme-probe mixture was added to the plate (50 µl per well, 0.5 µM IDE, 30 nM 4) the Multidrop Combi-nL Reagent Dispenser (Thermo Scientific). The final compound concentrations were 20 µM in both screens, and IDE inhibitor 1 was used as a positive control at 1 µM final concentration. After 30 min equilibration at room temperature, fluorescence anisotropy was recorded using an EnVision spectrophotometer (excitation 492 nm, emission 523 nm). Exclusion of compounds using auto-fluorescence measurements was not necessary in this case because the DOS compound libraries were designed to avoid fluorophores 34 . Primary assay data are deposited in PubChem BioAssay database 1259349 (Supplementary Data Set 1).
Metalloprotease cleavage activity assays using fluorogenic peptide substrates. Recombinant human IDE (R&D, no. 2496-ZN, or variants of His 6 -IDE expressed in house from E. coli), NEP (R&D, no. 1182-ZNC) and ACE (R&D, no. 929-ZN) were assayed using the fluorophore/quencher-tagged decapeptide substrate V, Mca-RPPGFSAFK(Dnp)-OH (R&D, no. ES005) according to the manufacturer's instructions and recommended buffers (Supplementary Table 5 ). For IDE assays the recommended buffer is 50 mM Tris pH 7.5, 1 M NaCl. The enzyme mixtures (48 µl) were transferred to a 96-well plate and combined with 2 µl of inhibitor in DMSO stock solutions, prepared in three-fold dilution series. The mixtures were allowed to equilibrate for 10 min and the enzymatic reaction was started by addition of substrate peptide in assay buffer (50 µl, 20 µM), mixed and monitored on a SpectraMAX fluorescence plate reader in kinetic mode for 5 min (excitation 320 nm, emission 405 nm). Similarly, THOP (R&D, no. 3439-ZN) and NLN (R&D, no. 3814-ZN) were assayed using substrate Mca-PLGPK(Dnp)-OH (Bachem, no. M-2710) according to the manufacturer's instructions and recommended buffers (Supplementary Table 5 ). Matrix metalloproteinase-1 (MMP-1, R&D, no. 901-MP) was activated and assayed according to the manufacturer's instructions with substrate Mca-KPLGL-Dpa-AR-NH 2 (R&D, no. ES010). For the insulin and glucagon competition experiments, an IDE enzyme mixture (R&D no. 2496-ZN, 48 µl, 85 ng ml −1 final dilution) in assay buffer (50 mM Tris pH 7.5, 1 M NaCl) was combined with freshly prepared Humulin-R (Eli Lilly) in the same buffer (25 µl, 50 µM final dilution) or GlucaGen (Novo Nordisk, 25 µl, 50 µM final concentration), respectively, and inhibitors in DMSO stock solutions (2 µl). , and incubated at 25 °C for 10 min. This procedure was optimized to result in ~85% degradation of glucagon in no-inhibitor DMSO control reactions. All reactions were terminated at the same time by the addition of 1 µl of inhibitor 2 (5 µM) 23 and chilled on ice. The remaining glucagon in each reaction was quantified using 10 µl of the quenched enzymatic reaction using the Homogeneous Time-Resolved FRET Glucagon assay (CisBio 62GLCPEF) in 20 µl total volume according to the manufacturer's instructions (384-well plate Greiner 784904 non-binding). Fluorescence was measured using a Tecan M1000Pro plate reader (excitation 340 nm, emission 665 and 620 nm, lag time 60 µs) according to the assay manufacturer's recommendations. Blank wells and a glucagon standard curve were included in the assay. Manufacturer-reported specificity validation: glucagon, 100%; glucagon fragment 1-18, <1.81%, glucagon fragment 19-29, <0.03%, oxyntomodulin, <0.07%; glicentin,<0.07%; GLP-1 (7-36) amide, <0.06%, GLP-1 (7-37); <0.11%, GLP-2, <0.3%; glicentin-related pancreatic peptide <0.01%.
ELISA-based assay for measurement of IDE-mediated degradation of amylin.
A solution of 0.75 µg ml −1 recombinant human IDE (R&D, no. 2496-ZN) in pH 7.5 buffer containing 20 mM HEPES, 135 mM NaCl (24 µl) was transferred to a 200-µl tube strip, and combined with 1 µl of each inhibitor in DMSO stock solutions or prepared as a three-fold dilution series. A solution of amylin (25 µl, Millipore no. E8051-K) was added to a final concentration of 175 pM (685 pg ml −1 ) and incubated at 25 °C for 15 min. This procedure was optimized to result in ~85% degradation of amylin in no-inhibitor DMSO control reactions. All reactions were terminated at 15 min by the addition of 50 µl of a solution of ELISA Assay Buffer containing inhibitor 2 (ref. 23 ) (200 nM) and chilled on ice. The remaining amylin in each reaction was quantified by transferring 100 µl of the quenched enzymatic reaction to the ELISA plate (Millipore, no. EZHA-52K), and incubated for 1 h at room temperature as indicated in the ELISA manufacturer's instructions. Following the washing steps and antibody detection procedure using the alkaline phosphatase substrate 4-methylumbelliferyl phosphate, fluorescence was measured using a Tecan M1000Pro plate reader (excitation 355 nm, emission 460 nm) according to the assay manufacturer's recommendations. Blank wells and an amylin standard curve in the same DMSO-treated reaction buffer were included in the assay. Manufacturer reported specificity: the capture antibody recognizes the N terminus of human amylin (disulfide bridge Cys2-Cys7), but not the reduced form of amylin; and the detection antibody recognizes the C terminus of human amylin, but not a 1-20 fragment of amylin.
Dual-antibody HTRF assay for IDE-mediated degradation of Aβ(40).
A solution of 2.9 µg ml −1 recombinant human IDE (R&D, no. 2496-ZN) in pH 7.5
Articles NaTUrE CHEmICal BIology buffer containing 20 mM HEPES, 135 mM NaCl (24 µl) was transferred to a 200-µl tube strip, and combined with 1 µl of each inhibitor in DMSO stock solutions prepared as a three-fold dilution series. A solution of Aβ (40) in assay buffer Diluent (25 µl, CisBio 62INSPEB) was added to a final concentration of 1,600 pg ml −1 and incubated at 30 °C for 35 min. This procedure was optimized to result in ~85% degradation of Aβ (40) in no-inhibitor DMSO control reactions. All reactions were terminated at the same time by adding 25 µl of inhibitor 2 (ref. 23 ) in the same buffer (200 nM) and chilled on ice. The remaining Aβ (40) was quantified using 10 µl of the quenched enzymatic reaction in a homogeneous time-resolved FRET Aβ(40) assay (CisBio 62B40PEG) in 20 µl total volume according to the manufacturer's instructions (384-well plate Greiner 784904 non-binding). Fluorescence was measured using a Tecan M1000Pro plate reader (excitation 320 nm, emission 665 and 620 nm, lag time 60 µs) according to the assay manufacturer's recommendations. Blank wells and an Aβ(40) standard curve were included in the assay. Manufacturer-reported specificity: no crossreaction with amyloid β1-42 or 1-43, limit of detection: 13.64 pg ml −1 , assay range: 25-1,600 pg ml
Mass spectrometry IDE-mediated glucagon cleavage analysis using MALDI-TOF. A solution of 0.5 µg ml −1 recombinant human IDE (R&D, no. 2496-ZN) in pH 7.5 buffer containing 20 mM Tris, 100 mM NaCl (200 µl) was transferred to a 1.5-ml LoBind Eppendorf tube, and combined with 1 µl of each inhibitor in DMSO stock solutions. A solution of human glucagon (Eli Lilly) in the same buffer (200 µl) was added to a final concentration of 10 ng ml −1 , and incubated at room temperature. At the indicated timepoints a 25-µl aliquot of each reaction was quenched by transferring into a new Eppendorf tube preloaded with 5 µl of 1% TFA solution, and chilled on ice. For MALDI-TOF analysis, an aliquot of quenched reaction (10 µl) was combined with an equal volume (10 µl) of a freshly prepared saturated solution of alpha-cyano-4-hydroxycinnamic acid in 1:1 (v/v) acetonitrile:water containing 0.1% trifluoroacetic acid, spotted on the MALDI plate target and allowed to air-dry slowly while covered. Spectra were recorded on a Bruker Ultraflextreme MALDI-TOF/TOF mass spectrometer and FlexControl software, calibrated using ProteoMass peptide calibration kit (Sigma, no. MSCAL2).
Expression and purification of recombinant cysteine-free human IDE (CF-IDE-E111Q).
Cysteine-free, catalytically inactive human IDE (CF-IDE-E111Q) was expressed in BL21-CodonPlus(DE3)-RIL E. coli cells and purified using Ni-affinity and anion exchange chromatography as previously described 11 . Generating the IDE-37, IDE-63 co-crystal complexes as well as the IDE-63-glucagon ternary complex required three consecutive cycles of purification using a HiLoadTM 16/16 Superdex S200 size exclusion column (GE LifeScience) in 20 mM Tris pH 8.0, 50 mM NaCl, 0.1 mM PMSF. An additional 20 mM EDTA pH 8.0 was added to all the buffers associated with IDE-63-glucagon purification to inhibit the catalytic degradation of glucagon by IDE. After purifying CF-IDE-E111Q by size exclusion chromatography once, CF-IDE-E111Q eluent fractions were pooled and mixed with a two-fold molar excess of 37 or 63. The protein-drug mixture was incubated for a minimum of 30 min on ice to facilitate complex formation. The proteininhibitor complexes were then subjected to two further rounds of size exclusion chromatography with the addition of a two-fold molar excess of inhibitors 37 or 63 and/or glucagon (0 or two-fold molar excess), respectively, to the eluent after each round of purification. After a final 30 min incubation step, IDE-37, IDE-63 or the IDE-63-glucagon complex was concentrated to 15-20 mg ml −1 and used immediately for crystallization.
Co-crystallization and X-ray diffraction of IDE-37 and IDE-63-Glucagon. The complexes IDE-37, IDE-63 and IDE-63-glucagon were crystallized by hanging drop vapor diffusion. Specifically, 1 µl of mother liquor (0.1 M HEPES pH 6.8, 12% Tacsimate pH 7, 20% PEGMME-5000, 10% 1,4-dioxane) was mixed with 1 µl of 20 mg ml −1 IDE-37 and incubated at room temperature. For the IDE-63 and IDE-63-glucagon complexes, 1 µl of mother liquor (0.1 M HEPES pH 7.0, 5% Tacsimate pH 7, 13% PEGMME-5000, 10% 1,4-dioxane) was mixed with 1 µl of 15 mg ml
IDE-63 or IDE-63-glucagon and incubated at room temperature. Crystals for all the CF-IDE-E111Q protein complexes were visible after 3 days and displayed an urchin-like morphology. When harvesting crystals for X-ray diffraction, the crystals were first separated into individual needles. The largest needles were soaked in a cryoprotective crystallography buffer composed of mother liquor containing 30% glycerol and then snap-frozen in liquid nitrogen. X-ray diffraction data for IDE-37 was obtained from a single crystal at a temperature of 100 K and wavelength of 1.116 Å using the SIBYLS Beamline located at the Advanced Light Source (ALS), operated by the Lawrence Berkeley National Laboratory. Diffraction data for the IDE-63 and IDE-63-glucagon complexes were obtained from a single crystal at 100 K using the AMX and FMX beamlines, respectively, at the National Synchrotron Light Source II operated by the Brookhaven National Laboratory. Data for IDE-63 was collected at a wavelength of 0.978 Å and data for IDE-63-glucagon was collected at 0.979 Å. IDE-37, IDE-63 and IDE-63-glucagon structure refinement. Diffraction data for IDE-37 were indexed, integrated and scaled using X-ray detector software and data for IDE-63 and IDE-63-glucagon were indexed, integrated and scaled using X-ray detector software via autoPROC (ref. 52 ). All crystals were established in space group P6 5 (Supplementary Table 7) 52 . We phased the data via molecular replacement in Phaser (ref. 53 ), using our previously solved structure of human CF-IDE-E111Q complexed with the macrocyclic inhibitor 3 (PDB ID 4LTE) (ref.
11
), as our search model. Coot (ref. 54 ) was used to build the structural model for both IDE-37, IDE-63 and IDE-63-glucagon. All refinements to the model were conducted in PHENIX (ref. 55 ), using NCS (torsion-angle) and TLS (nine groups per chain). The finished model for IDE-17 had an R work of 0.161 and an R free of 0.203 with 0.0% of residues forming Ramachandran outliers and 97.5% of residues falling within Ramachandran favored regions. The finished model for IDE-63 had an R work of 0.162 and an R free of 0.211 with 0.1% of residues forming Ramachandran outliers, and 95.7% of residues falling within Ramachandran favored regions. Our model for IDE-63-glucagon had an R work of 0.177 and an R free of 0.222 with 0.1% of residues forming Ramachandran outliers and 96.2% of residues falling within Ramachandran favored regions. Additional data collection and crystal refinement statistics are listed in Supplementary Table 7) .
Structure visualization, superimposition and distance-difference matrix plots. We used PHENIX 55 to compute the distance-difference matrix plots between apo-IDE (PDB ID 2JG4), Fab-IDE (PDB ID 4IOF) 42 IDE-37 (PDB ID 6BYZ), IDE-63 (PDB ID 6MQ3 and IDE-63-glucagon (PDB ID 6EDS). PyMOL was used to generate the graphics for the structural models as well as the overlays of previously solved structures with IDE bound to insulin (PDB ID 2WBY), glucagon (PDB ID 2G49), amylin (PDB ID 2G48) and amyloid-β (1-40) (PDB ID 2G47) 40 . . Non-hydrogen atoms were refined anisotropically, and hydrogen atoms were allowed to ride on the respective atoms. Crystal data as well as details of data collection and refinement are summarized in Supplementary Table 9 
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